Per diffusione immediata - 9 marzo 2010

Seneffe - Belgio, 9 marzo 2010, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) ha comunicato oggi che in seguito ai recenti sviluppi, il periodo di accettazione dell'offerta pubblica di acquisto lanciata da Eckert & Ziegler AG e SMI Steglitz Medinvest sull'insieme dei titoli IBt ? stato prorogato al 17 marzo 2010, ore 16.00.

A proposito di IBt Bebig
... Contributing to saving lives!

IBt Bebig ? un gruppo europeo attivo nel segmento Dispositivi medicali del settore delle cure sanitarie.

The core business of the IBt Bebig group is the cancer treatment by radiation technology. Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis. Depending on the application, the implant can take the shape of a plaque, a seed or a catheter. The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient's quality of life. Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers.

The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India. Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH.BR - Bloomberg : IBTB BB).

Contact
Paul-Emmanuel Goethals
Head of Investor Relations & Communication
Tel: +32.64.520.808

E-mail: ir@ibt-bebig.eu
Internet: www.ibt-bebig.eu



Copyright Hugin

Questo comunicato ? distribuito da Hugin. L'emittente ? l'unico responsabile per il contenuto del comunicato.

[CN#163956]